Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy

Kenichi Sakurai, Katsuhisa Enomoto, Akira Kitajima, Mayumi Tani, Sadao Amano, Motomi Shiono

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

We evaluated the significance of indoleamine 2,3-dioxygenase (IDO) in recurrent breast cancer patients during chemotherapy. IDO activity can be measured by tryptophan (Trp)/kynurenine (Kyn) ratio. Trp and Kyn were measured by High Performance Liquid Chromatography (HPLC). The correlations among Trp/Kyn ratio and immunosuppressive acidic protein (IAP) value in pre-chemotherapies or post-chemotherapies were studied. There were no correlations between pre-chemotherapy and post-chemotherapy in IAP values and Trp/Kyn ratio with weekly paclitaxel therapy. And there were no correlations between pre-chemotherapy and post-chemotherapy in IAP values, but Trp/Kyn ratio in post-chemotherapy was higher than re-chemotherapy with tri-weekly docetaxel therapy. These results suggest that the weekly paclitaxel therapy may be less invasive for recurrent breast cancer patients than the tri-weekly docetaxel therapy.

Original languageEnglish
Pages (from-to)2265-2267
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume35
Issue number12
Publication statusPublished - Nov 2008

Fingerprint

Dive into the research topics of 'Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy'. Together they form a unique fingerprint.

Cite this